Author: Kah Peng

ROCHESTER, Minn., July 18, 2018 – Vyriad Inc., a clinical-stage, privately held biotechnology company focused on the development of powerful first-in class oncolytic virotherapies, is pleased to announce a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to expand its ongoing Phase 1 clinical...

.entry_title .date { display: none; } p { font-size: 16px; margin: 1em 0 1em 30%; } .intro { font-size: 24px; color: #000; margin: 1em 0 1em 30%; } .photo { margin-right: 30%; } ul p { margin: 0 0 0 30% !important; } ul li { margin-bottom: 1em; } ul p a { font-size: 16px; } @media screen and (max-width: 767px) { p { font-size: 16px; margin: 1em 0 1em 0;...